Targeting bile‐acid signalling for metabolic diseases
Open accessThe DOI matches its Crossref record; 165 of the 169 references it cites were found in a registry or an index.
Abstract
Bile acids are increasingly being appreciated as complex metabolic integrators and signalling factors and not just as lipid solubilizers and simple regulators of bile-acid homeostasis. It is therefore not surprising that a number of bile-acid-activated signalling pathways have become attractive therapeutic targets for metabolic disorders. Here, we review how the signalling functions of bile acids can be exploited in the development of drugs for obesity, type 2 diabetes, hypertriglyceridaemia and atherosclerosis, as well as other associated chronic diseases such as non-alcoholic steatohepatitis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Through FXR activation, OCA modulates bile acid synthesis, absorption, transport, secretion, and metabolism, with a net effect of choleresis.(157,158)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [157]
In the citing paper
“In animal models, FXR activation has demonstrated antifibrotic and anti-inflammatory properties as well.(157)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [157]
In the citing paper
“After conjugation with either taurine or glycine, primary bile acids are released into the intestine to assist with lipid digestion and are recycled back into the liver (Thomas et al., 2008).”
From The Microbiota-Gut-Brain Axis (2019) · cites this paper as Thomas et al., 2008
In the citing paper
“By activating nuclear farnesoid X receptor (FXR) and plasma membrane TGR5 receptor, bile acids were shown to regulate systemic lipid, cholesterol, and glucose metabolism, as well as energy and immune homeostasis (Calmus and Poupon, 2014;de Aguiar Vallim et al., 2013;Thomas et al., 2008).”
From The Microbiota-Gut-Brain Axis (2019) · cites this paper as Thomas et al., 2008
In the citing paper
“In addition, FXR regulates other pathways with direct antiinflammatory and antifibrotic effects. 13-15”
From A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis (2016) · cites this paper as [13]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Identification of a nuclear receptor for bile acids
Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., & Shan, B. (1999) · Science · doi:10.1126/science.284.5418.1362 · Cited by 2,714
Özcan, U., Yilmaz, E., Özcan, L., Furuhashi, M., Vaillancourt, E., Smith, R. O., Görgün, C. Z., & Hotamisligil, G. S. (2006) · Science · doi:10.1126/science.1128294 · Cited by 2,413
Bile Acids: Natural Ligands for an Orphan Nuclear Receptor
Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1365 · Cited by 2,274
Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation
Watanabe, M., Houten, S. M., Mataki, C., Christoffolete, M. A., Kim, B. W., Sato, H., Messaddeq, N., Harney, J. W., Ezaki, O., Kodama, T., et al. (2006) · Nature · doi:10.1038/nature04330 · Cited by 2,220
Self-citationThe Enzymes, Regulation, and Genetics of Bile Acid Synthesis
Russell, D. W. (2003) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.72.121801.161712 · Cited by 2,069
Research works printed but not linked: 1
- Harnish, D. C. et al. A synthetic farnesoid X receptor (FXR) agonist protects against diet-induced dyslipidemia. J. Clin. Lipidol. 1, 362 (2007).
Cited by
Items 501–600 of 1,002
Wei, X., Yin, F., Wu, M., Xie, Q., Zhao, X., Zhu, C., Xie, R.-Q., Chen, C., Liu, M., Wang, Y., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.10.011 · Cited by 47
Poša, M., & Sebenji, A. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.11.008 · Cited by 41
The adipokine Retnla modulates cholesterol homeostasis in hyperlipidemic mice
Lee, M., Lim, C.-J., Lee, Y.-H., Park, J., Sonn, S. K., Lee, M.-N., Jung, I., Jeong, S., Jeon, S., Lee, M., et al. (2014) · Nature Communications · doi:10.1038/ncomms5410 · Cited by 47
Olesen, N. E., Westh, P., & Holm, R. (2015) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2015.03.069 · Cited by 41
Intercellular Lipid Mediators and GPCR Drug Discovery
Im, D. (2013) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2013.080 · Cited by 45
“Bile acids are being increasingly appreciated as complex metabolic integrators and signaling factors (Thomas et al., 2008), although they have long been known to be essential in dietary lipid absorption and cholesterol catabolism (Watanabe et al., 2006).”
BackgroundGuo, H., Hassan, H. M., Zhang, Y., Dong, S.-Z., Ding, P., Wang, T., Sun, L., Zhang, L., & Jiang, Z. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfw098 · Cited by 43
Dietary Composition and Cardiovascular Risk: A Mediator or a Bystander?
Korakas, E., Dimitriadis, G., Raptis, A. E., & Lambadiari, V. (2018) · Nutrients · doi:10.3390/nu10121912 · Cited by 52
“Primary bile acids, cholic acid (CA), and chenodeoxycholic acid (CDCA) are metabolized into the secondary bile acids deoxycholic acid (DCA) and lithocholic acid (LCA), which signal to the host through G-protein-coupled receptor 1 (also called TGR5) and the bile acid receptor FXR, both of which affect metabolism [201].”
BackgroundNigám, S. K., Bush, K. T., Bhatnagar, V., Poloyac, S. M., & Momper, J. D. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1818 · Cited by 47
“Along with cyclooxygenase and lipoxygenase, CYP450 enzymes—principally CYP2C, CYP2J, CYP4A, and CYP4F isoforms—control the generation of arachidonic acid metabolites to bioactive eicosanoids.(16-109) The diverse signaling compounds REVIEW”
BackgroundSekine, S., Ogawa, R., Ojima, H., & Kanai, Y. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01990.x · Cited by 44
O-GlcNAc: A Bittersweet Switch in Liver
Zhang, K., Yin, R., & Yang, X. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00221 · Cited by 46
“Given their effects on lowering inflammatory and fibrogenic processes, a number of synthetic FXR agonists are being used to treat different hepatic and metabolic disorders (59, 60).”
BackgroundActivation of TGR5 promotes osteoblastic cell differentiation and mineralization
Wang, Q., Wang, G., Wang, B., & Yang, H. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.093 · Cited by 44
Chen, Y., Zhu, L., Hu, W., Wang, Y., Wen, X., & Yang, J. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154264 · Cited by 43
Crosstalk between Gut Microbiota and Bile Acids in Cholestatic Liver Disease
Shi, Q., Yuan, X., Zeng, Y., Wang, J., Zhang, Y., Chen, X., & Li, L. (2023) · Nutrients · doi:10.3390/nu15102411 · Cited by 42
“BA-coenzyme A (BA-CoA) synthetase and BA-CoA: amino acid N-acyltransferase then mediate the conversion of the primary BAs integrated with the amino acid taurine or glycine into taurocholic acid (TCA), taurochenodeoxycholic acid, glycine cholic acid (GCA), and glycochenodeoxycholic acid [16].”
BackgroundAvicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators
Pellicciari, R., Gioiello, A., Sabbatini, P., Venturoni, F., Nuti, R., Colliva, C., Rizzo, G., Adorini, L., Pruzanski, M., Roda, A., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200256d · Cited by 42
Self-citationModulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics
Cho, M. S., Kim, S. Y., Suk, K. T., & Kim, B. (2018) · The Journal of Microbiology · doi:10.1007/s12275-018-8346-2 · Cited by 46
Zhang, F., Yuan, W., Wei, Y., Zhang, D., Duan, Y., Li, B., Wang, X., Xi, L., Zhou, Y., & Wu, X. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.05.031 · Cited by 42
Semisynthetic bile acids: a new therapeutic option for metabolic syndrome
Lazarević, S., Đanić, M., Goločorbin-Kon, S., Al‐Salami, H., & Mikov, M. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104333 · Cited by 42
Gupta, B., Liu, Y., Chopyk, D. M., Rai, R. P., Desai, C., Kumar, P., Farris, A. B., Nusrat, A., Parkos, C. A., Anania, F. A., et al. (2020) · The FASEB Journal · doi:10.1096/fj.201902687r · Cited by 40
Zhang, Z., Zhou, H., Zhou, X., Sun, J., Liang, X., Lv, Y., Bai, L., Zhang, J., Gong, P., Liu, T., et al. (2020) · British Journal Of Nutrition · doi:10.1017/s0007114520003001 · Cited by 42
“Approximately 5 % enter the colon and are partially reabsorbed, whereas some aremetabolised by intestinal microorganisms before being excreted out of the body(36).”
BackgroundPeripheral targets in obesity treatment: a comprehensive update
Chatzigeorgiou, A., Kandaraki, E., Papavassiliou, A. G., & Koutsilieris, M. (2014) · Obesity Reviews · doi:10.1111/obr.12163 · Cited by 52
“TGR5-dependent manner and decrease hepatic VLDL production in an FXR-dependent manner (128).”
BackgroundMobraten, K., Haugbro, T., Karlstrom, E., Kleiveland, C. R., & Lea, T. (2014) · Journal of Receptors and Signal Transduction · doi:10.3109/10799893.2014.986744 · Cited by 42
“analysis has concluded that human TGR5 is divergent from rodent TGR5 (23).”
BackgroundImpaired Bile Acid Homeostasis in Children with Severe Acute Malnutrition
Zhang, L., Voskuijl, W. P., Mouzaki, M., Groen, A. K., Alexander, J., Bourdon, C., Wang, A., Versloot, C. J., Giovanni, V. D., Wanders, R. J. A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155143 · Cited by 42
“Hydrophobic bile acids (such as LCA) can contribute to intestinal inflammation [19].”
BackgroundReinicke, M., Schröter, J., Müller‐Klieser, D., Helmschrodt, C., & Ceglarek, U. (2018) · Analytica Chimica Acta · doi:10.1016/j.aca.2018.02.049 · Cited by 42
Rethinking Bile Acid Metabolism and Signaling for Type 2 Diabetes Treatment
Zaborska, K. E., & Cummings, B. P. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1092-3 · Cited by 42
Roles of Hepatic Drug Transporters in Drug Disposition and Liver Toxicity
Pan, G. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-7647-4_6 · Cited by 40
Duan, J., Dong, W., Xie, L., Fan, S., Xu, Y., & Li, Y. (2020) · Journal of Proteomics · doi:10.1016/j.jprot.2020.103767 · Cited by 39
Zhao, L., Ma, P., Peng, Y., Wang, M., Peng, C., Zhang, Y., & Li, X. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153477 · Cited by 43
Yang, C., Huang, S., Lin, Z., Chen, H., Xu, C., Lin, Y., Sun, H., Huang, F., Dai, L., & Guo, F. (2022) · Food & Function · doi:10.1039/d2fo02079c · Cited by 40
Tognolini, M., Incerti, M., Hassan‐Mohamed, I., Giorgio, C., Russo, S., Bruni, R., Lelli, B., Bracci, L., Noberini, R., Pasquale, E. B., et al. (2012) · ChemMedChem · doi:10.1002/cmdc.201200102 · Cited by 39
Bile Formation and the Enterohepatic Circulation
Dawson, P. A. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382026-6.00053-1 · Cited by 40
Zhao, Y., Wei, S., Chen, L., Zhou, X., & Ma, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1164202 · Cited by 45
Wu, M., Cheng, Y., Zhang, R., Han, W., Jiang, H., Bi, C., Zhang, Z., Ye, M., Lin, X., & Liu, Z. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117228 · Cited by 41
Elobixibat for the treatment of constipation
Wong, B. S., & Camilleri, M. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.753056 · Cited by 38
“These include ability to improve blood lipid profiles and glycemic control [28-30].”
BackgroundMechanisms Underlying the Anti-Aging and Anti-Tumor Effects of Lithocholic Bile Acid
Arlia‐Ciommo, A., Piano, A., Svistkova, V., Mohtashami, S., & Titorenko, V. I. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150916522 · Cited by 40
“Furthermore, cholic and chenodeoxycholic bile acids have been successfully used for increasing lipid absorption and improving liver function, thereby preventing progressive liver disease in patients with inborn errors of bile acid synthesis [141,142,149].”
BackgroundInfluentialLi, K., Zou, J., Li, S., Guo, J., Shi, W., Wang, B., Zhang, P., Zhang, H., Zhang, P., Miao, Z., et al. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.100980 · Cited by 44
“Bile acids regulate metabolic improvement and glucose homeostasis via activation of these signaling pathways [5,11,12].”
BackgroundZhang, Y., Gu, Y., Jiang, J., Cui, X., Cheng, S., Liu, L., Huang, Z., Liao, R., Zhao, P., Yu, J.-Y., et al. (2022) · npj Science of Food · doi:10.1038/s41538-022-00156-0 · Cited by 41
Long noncoding RNAs in TDP-43 and FUS/TLS-related frontotemporal lobar degeneration (FTLD)
Lourenco, G. F., Janitz, M., Huang, Y. M., & Halliday, G. M. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.07.011 · Cited by 43
Nuclear hormone receptors in diabetic nephropathy
Wang, X. X., Jiang, T., & Levi, M. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.56 · Cited by 38
“Activation of FXR has an important role in maintaining glucose, lipid, and bile acid homeostasis in the enterohepatic system”
BackgroundMulti-omics: Opportunities for research on mechanism of type 2 diabetes mellitus
Wang, S., Yong, H., & He, X. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i7.1070 · Cited by 46
Gao, X., Ruan, Y., Zhu, X., Lin, X., Yan, X., Li, X., Mai, M., & Guo, H. (2021) · Inflammation · doi:10.1007/s10753-021-01573-1 · Cited by 39
Bile acid and nonalcoholic steatohepatitis: Molecular insights and therapeutic targets
Cheng, Z., Chen, Y., Schnabl, B., Chu, H., & Yang, L. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.06.009 · Cited by 41
“Several researches have observed that FXR-deficient (FXR–/–) mice developed hepatic steatosis or hypertriglyceridemia [72,73], which indicated that FXR was closely related to hepatic lipid metabolism.”
BackgroundGustducin couples fatty acid receptors to GLP-1 release in colon
Li, Y., Kokrashvili, Z., Mosinger, B., & Margolskee, R. F. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00471.2012 · Cited by 37
“The lumen of the colon lacks dietary sugars, but is filled with microbiota, nondigestible matter, and fermentation products, such as short-chain fatty acids (SCFAs), ammonia, phenols, amines, and bile acids (12, 23, 50, 84).”
Melatonin ameliorates alcohol‐induced bile acid synthesis by enhancing miR‐497 expression
Kim, Y. D., Hwang, S., Lee, E., Kim, H., Chung, M.-J., Elfadl, A. K., Lee, S., Nedumaran, B., Harris, R. A., & Jeong, K. (2017) · Journal of Pineal Research · doi:10.1111/jpi.12386 · Cited by 40
Steinacher, D., Claudel, T., & Trauner, M. (2017) · Digestive Diseases · doi:10.1159/000454853 · Cited by 40
Ladurner, A., Zehl, M., Grienke, U., Hofstadler, C., Faur, N., Pereira, F. C., Berry, D., Dirsch, V. M., & Rollinger, J. M. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00468 · Cited by 43
“TGR5 acts in a tissue-specific manner via increasing intracellular levels of cAMP and thereby modulating several downstream signaling pathways (Kawamata et al., 2003; Thomas et al., 2008).”
BackgroundBeneficial effects of bile acid receptor agonists in pulmonary disease models
Comeglio, P., Morelli, A., Adorini, L., Maggi, M., & Vignozzi, L. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1385760 · Cited by 43
Guo, L., Wang, L., Liu, F., Li, B., Tang, Y., Yu, S., Zhang, D., & Huo, G. (2019) · Journal of Functional Foods · doi:10.1016/j.jff.2019.103497 · Cited by 41
Habitual animal fat consumption in shaping gut microbiota and microbial metabolites
Wan, Y., Tong, W., Zhou, R., Li, J., Yuan, J., Wang, F., & Li, D. (2019) · Food & Function · doi:10.1039/c9fo01490j · Cited by 40
Tsai, S. J., Zhong, Y.-S., Weng, J.-F., Huang, H.-H., & Hsieh, P.-Y. (2010) · Journal of Chromatography A · doi:10.1016/j.chroma.2010.11.062 · Cited by 37
Retinoid X Receptor Heterodimer Variants and Cardiovascular Risk Factors
Nohara, A., Kobayashi, J., & Mabuchi, H. (2009) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.no786 · Cited by 41
Zhang, C.-E., Niu, M., Li, R., Feng, W., Ma, X., Dong, Q., Ma, Z., Li, G.-Q., Meng, Y.-K., Wang, Y., et al. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00085 · Cited by 37
“Because bile acids are closely related to the occurrence and development of cholestasis, special attention has been paid to the bile acid level related to the treatment of cholestasis (Thomas et al., 2008).”
BackgroundBile acid profiles in diabetic (db/db) mice and their wild type littermates
Chen, C., Hu, B., Wu, T., Zhang, Y., Xu, Y., Feng, Y., & Jiang, H. (2016) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2016.09.023 · Cited by 40
Gao, X., Lin, X., Yan, X., Zhu, X., Li, X., Chen, M., Huang, Z., & Guo, H. (2023) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2023.109347 · Cited by 39
Regulating bile acids signaling for NAFLD: molecular insights and novel therapeutic interventions
Wei, M., Tu, W., & Huang, G. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1341938 · Cited by 46
“BAs can exert a wide range of regulatory effects through these receptors, including glucose and lipid metabolism, BA homeostasis and energy expenditure, immune and inflammatory responses, and improving insulin sensitivity (Thomas et al., 2008).”
BackgroundFXR-dependent reduction of hepatic steatosis in a bile salt deficient mouse model
Kunne, C., Acco, A., Duijst, S., de Waart, D. R., Paulusma, C. C., Gaemers, I. C., & Elferink, R. P. J. O. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.02.004 · Cited by 44
The microbiome and its pharmacological targets: therapeutic avenues in cardiometabolic diseases
Neves, A. L., Chilloux, J., Sarafian, M. H., Rahim, M. B. A., Boulangé, C. L., & Dumas, M.-E. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.09.013 · Cited by 36
Structural characterization of human cholesterol 7α-hydroxylase
Tempel, W., Grabovec, I. P., MacKenzie, F., Dichenko, Y. V., Usanov, S. A., Gilep, A. A., Park, H., & Strushkevich, N. V. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m050765 · Cited by 39
“A modulation of both oxysterol and bile acid signaling pathways has recently emerged as a source of promising novel drug targets to treat common metabolic and hepatic diseases (19).”
BackgroundDe novo cholesterol biosynthesis in bacteria
Lee, A. K., Wei, J. H., & Welander, P. V. (2023) · Nature Communications · doi:10.1038/s41467-023-38638-8 · Cited by 39
Epigenomic regulation of bile acid metabolism: Emerging role of transcriptional cofactors
Smith, Z., Ryerson, D., & Kemper, J. K. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.04.008 · Cited by 36
“Not surprisingly, therefore, these bile acid-activated signaling pathways have been attractive molecular targets for treating metabolic diseases (Thomas et al 2008,Modica and Moschetta 2006,Staels and Kuipers 2007,Cariou and Staels 2007,Zhang and Edwards 2008,Fiorucci et al 2009,Wagner et al…”
BackgroundInfluentialKolhatkar, V., & Polli, J. E. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.02.012 · Cited by 35
“Compound 1 is the C-7 a hydroxyl conjugate, where reactant CDCA possesses a C-7 a hydroxyl group (i.e. axially oriented) (Thomas et al., 2008).”
Masubuchi, N., Sugihara, M., Sugita, T., Amano, K., Nakano, M., & Matsuura, T. (2015) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2015.08.016 · Cited by 39
Bile acid and its bidirectional interactions with gut microbiota: a review
He, S., Li, L., Yao, Y., Su, J., Lei, S., Zhang, Y., & Zeng, H. (2023) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2023.2262020 · Cited by 39
“More and more studies have shown that BAs have been shown to be targets for activating metabolic signaling pathways, thus playing an important role in the treatment of metabolic diseases such as obesity, type 2 diabetes mellitus, hyperlipidemia, and atherosclerosis (thomas et al. 2008).”
TGR5 Sequence Variation in Primary Sclerosing Cholangitis
Hov, J. R., Keitel, V., Schrumpf, E., Häussinger, D., & Karlsen, T. H. (2011) · Digestive Diseases · doi:10.1159/000324138 · Cited by 35
“]). Common variants may also change gene splicing sites causing alternative splicing and expression of different proteins [ ,”
BackgroundGlastras, S. J., Wong, M. G., Chen, H., Zhang, J., Zaky, A. A., Pollock, C. A., & Saad, S. (2015) · Nutrition & Metabolism · doi:10.1186/s12986-015-0032-3 · Cited by 37
“and lipid metabolism [15-21].”
Rimoldi, S., Benedito‐Palos, L., Terova, G., & Pérez‐Sánchez, J. (2015) · Reviews in Fish Biology and Fisheries · doi:10.1007/s11160-015-9408-8 · Cited by 46
“Furthermore, bile acids are versatile molecules that activate nuclear receptors and cell-signaling pathways and play critical roles in regulating lipid, glucose, and energy metabolism (Lefebvre et al. 2009; Thomas et al. 2008).”
BackgroundMcGettigan, B. M., McMahan, R. H., Luo, Y., Wang, X. X., Orlicky, D. J., Porsche, C., Levi, M., & Rosen, H. R. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.731042 · Cited by 35
Kakimoto, T., Kanemoto, H., FUKUSHIMA, K., Ohno, K., & Tsujimoto, H. (2017) · American Journal of Veterinary Research · doi:10.2460/ajvr.78.12.1406 · Cited by 56
Zhu, P., Zhang, J., Chen, Y., Yin, S., Su, M., Xie, G., Brouwer, K. L. R., Liu, C., Lan, K., & Jia, W. P. (2018) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-018-1183-7 · Cited by 37
“On the side of host, the BA receptors, such as nuclear farnesoid X receptor (FXR) and G proteincoupled membrane receptor 5 (TGR5), have become major targets for studies of metabolic diseases [5, 6].”
The RNA binding protein human antigen R is a gatekeeper of liver homeostasis
Subramanian, P., Gargani, S., Palladini, A., Chatzimike, M., Grzybek, M., Peitzsch, M., Papanastasiou, A. D., Pyrina, I., Ntafis, V., Gercken, B., et al. (2021) · Hepatology · doi:10.1002/hep.32153 · Cited by 35
“18, 35 ] Continuing our search for protective pathways , which could fail in the absence of HuR , we sought to identify identify mRNAs that were bound to and regulated by HuR.”
BackgroundYang, C., Wan, M., Xu, D., Pan, D., Xia, H., Yang, L., & Sun, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910858 · Cited by 36
Zhao, Y., He, Z., Hao, W., Zhu, H., Liu, J., Ma, K. Y., He, W., & Chen, Z. (2021) · Food & Function · doi:10.1039/d1fo02906a · Cited by 38
Ciocan, D. M., Spatz, M., Trainel, N., Hardonnière, K., Domenichini, S., Mercier‐Nomé, F., Desmons, A., Humbert, L., Durand, S., Kroemer, G., et al. (2022) · Cells · doi:10.3390/cells11060968 · Cited by 40
“BAs facilitate the absorption of dietary lipids and lipid-soluble nutrients [8] and act as signaling molecules by binding to host receptors, including the farnesoid-X receptor (FXR) and Takeda G-protein-coupled receptors (TGR5, also known as GPBAR1) [8].”
BackgroundInfluentialHo, R. H., Leake, B. F., Urquhart, B. L., Gregor, J. C., Dawson, P. A., & Kim, R. B. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06805.x · Cited by 39
Bile acid signaling after an oral glucose tolerance test
Matysik, S., Martin, J., Bala, M., Scherer, M., Schäffler, A., & Schmitz, G. (2011) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2011.05.003 · Cited by 41
Rahman, S. M., Baquero, K. C., Choudhury, M., Janssen, R. C., de la Houssaye, B. A., Sun, M., Miyazaki‐Anzai, S., Wang, S. F., Moustaïd‐Moussa, N., Miyazaki, M., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.03.040 · Cited by 37
Metabolic profiling reveals new serum biomarkers of lupus nephritis
Li, J., Xie, X.-W., Zhou, H., Wang, B., Zhang, M.-J., & Tang, F.-Y. (2017) · Lupus · doi:10.1177/0961203317694256 · Cited by 34
Draper, C. F., Vassallo, I., Cara, A. D., Milone, C., Comminetti, O., Monnard, I., Godin, J., Scherer, M., Su, M., Jia, W. P., et al. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201700703 · Cited by 40
Ye, G., Ding, D., Gao, H., Chi, Y., Chen, J., Wu, Z., Lin, Y., & Dong, S. (2019) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2019.07.192 · Cited by 35
Lin, M., Chen, X., Wang, Z., Wang, D., & Zhang, J. (2020) · Analytica Chimica Acta · doi:10.1016/j.aca.2020.07.067 · Cited by 35
Metabolomic-based clinical studies and murine models for acute pancreatitis disease: A review
Peng, Y., Hong, J., Raftery, D., Xia, Q., & Du, D. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166123 · Cited by 37
Gut microbiota-related metabolome analysis based on chromatography-mass spectrometry
Zhou, L., Yu, D., Zheng, S., Ouyang, R., Wang, Y., & Xu, G. (2021) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2021.116375 · Cited by 36
Kasai, Y., Kessoku, T., Tanaka, K., Yamamoto, A., Takahashi, K., Kobayashi, T., Iwaki, M., Ozaki, A., Nogami, A., Honda, Y., et al. (2022) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000503 · Cited by 35
“BAs have been shown to be involved in hydrophobicity and toxicity (36) and are said to be more hydrophobic in the order of ursodeoxycholic acid ,CA ,CDCA ,DCA ,LCA (37).”
Nuclear receptors in renal disease
Levi, M. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.04.003 · Cited by 34
“A clinical trial is in progress to examine the physiological effect of FXR activation by INT-747 in humans with nonalcoholic fatty liver disease [67].”
BackgroundA metabolomic perspective of griseofulvin-induced liver injury in mice
Liu, K., Yan, J., Sachar, M., Zhang, X., Guan, M., Xie, W., & Ma, X. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.09.002 · Cited by 37
“The liver is the center for bile acid synthesis and homeostasis [19, 20].”
BackgroundGut microbiome-metabolites axis: A friend or foe to colorectal cancer progression
Wu, H., Ma, W., Wang, Y., Wang, Y., Sun, X., & Zheng, Q. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116410 · Cited by 37
Wang, P., Ouyang, H., Bi, G., Liang, F., Wu, C., Wu, C., Jiang, X., Zhou, W., Li, D., Zhang, S., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156340 · Cited by 36
Quintero, P., Pizarro, M., Solís, N., Arab, J. P., Padilla, O., Riquelme, A. J., & Arrese, M. A. (2014) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-014-0336-1 · Cited by 36
“This is consistent with an FXRindependent effect given the fact that this BA is known to be a very weak FXR ligand [14, 34].”
BackgroundTherapy of Primary Sclerosing Cholangitis - Today and Tomorrow
Halilbasic, E., Fuchs, C. D., Hofer, H., Paumgartner, G., & Trauner, M. (2015) · Digestive Diseases · doi:10.1159/000440827 · Cited by 36
Pavagadhi, S., Natera, S., Roessner, U., & Balasubramanian, R. (2013) · Environmental Science & Technology · doi:10.1021/es4004125 · Cited by 33
Zhang, S., Pan, X., & Jeong, H. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.062836 · Cited by 34
“Based on the biologic function of FXR as a regulator of lipid and glucose metabolism, many FXR agonists are currently being investigated as potential therapeutic agents for the treatment of metabolic disorders, including hypercholesterolemia (Thomas et al., 2008; Fiorucci et al., 2012).”
BackgroundA Novel Protective Role for FXR against Inflammasome Activation and Endotoxemia
García‐Irigoyen, O., & Moschetta, A. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.03.014 · Cited by 33
He, B., Liu, Y., Hoang, T. K., Tian, X., Taylor, C. M., Luo, M., Tran, D. Q., Tatevian, N., & Rhoads, J. M. (2019) · Microbiome · doi:10.1186/s40168-019-0751-1 · Cited by 35
“Bile acids activate bile acid receptors such as FXR and TGR5, which regulate diverse immunological and metabolic pathways in the host [31, 32].”
Chemical Mechanisms of Colonization Resistance by the Gut Microbial Metabolome
Chang, P. V. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.9b00813 · Cited by 46
The Potential Role of Gut Microbiota in the Prevention and Treatment of Lipid Metabolism Disorders
He, Y.-J., & You, C. (2020) · International Journal of Endocrinology · doi:10.1155/2020/8601796 · Cited by 35
“Cholesterol 7 alpha-hydroxylase(CYP7A1) is used to convert cholesterol in the liver into bile acids and excreted in feces, which are the main pathways of cholesterol catabolism [54], whereas sterol-27 hydroxylase (encoded by CYP27A1) and CYP7B1 is mainly involved in the alternative pathway [55].”
BackgroundKanamaluru, D., Xiao, Z., Fang, S., Choi, S., Kim, D.-H., Veenstra, T. D., & Kemper, J. K. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01212-10 · Cited by 35
“Bile acids not only play dietary roles in the absorption of fat-soluble nutrients, but also function as endocrine signaling molecules that trigger genomic and nongenomic signaling pathways (4, 13, 30, 33).”
BackgroundPereira, T. N., Walsh, M. J., Lewindon, P. J., & Ramm, G. A. (2010) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v1.i2.69 · Cited by 37
[Retracted] A Review of Bile Acid Metabolism and Signaling in Cognitive Dysfunction‐Related Diseases
Weng, Z.-B., Chen, Y.-R., Lv, J.-T., Wang, M.-X., Chen, Z.-Y., Zhou, W., Shen, X.-C., Zhan, L.-B., & Wang, F. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/4289383 · Cited by 32
RetractedXia, J., Tang, N., Wu, X., & Ren, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1033145 · Cited by 34
“Bile acids (BAs) are a general term for a class of amphiphilic molecules produced by cholesterol metabolism, and their functions involve lipid digestion, absorption and hormone synthesis (5).”
BackgroundBile acids and microbes in metabolic disease
Sah, D. K., Arjunan, A., Park, S. Y., & Jung, Y. D. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i48.6846 · Cited by 36
Zheng, Q., Li, X., Huang, N., Li, F., Ge, J., Wang, D., Sun, R., & Liu, R. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.116110 · Cited by 38
Metadata
- Authors
- Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., & Schoonjans, K.
- Affiliations
- Institut de génétique et de biologie moléculaire et cellulaire (FR)
- University of Perugia (IT)
- Intercept Pharmaceuticals (United States) (US)
- Corresponding author
- Auwerx, Johan
- Schoonjans, Kristina
- Venue
- Nature Reviews Drug Discovery
- Published
- 2008-08
- Volume
- 7
- Issue
- 8
- Pages
- 678-693
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2078810890
- Cited by
- 1,422
- References
- 169
- Citations by year
- 2026: 81 · 2025: 92 · 2024: 106 · 2023: 107 · 2022: 113 · 2021: 90 · 2020: 83 · 2019: 82 · 2018: 78 · 2017: 81 · 2016: 75 · 2015: 75 · 2014: 71 · 2013: 77 · 2012: 47
- FWCI
- 5.13
- Type
- journal article
- Language
- en
- Open access
- green
- infoscience.epfl.ch
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Funders
- European Commission
- Institut National de la Santé et de la Recherche Médicale
- Fondation pour la Recherche Médicale
- Ligue Contre le Cancer
- Centre National de la Recherche Scientifique
- Société Française de Nutrition
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Pharmacology (medical) › Berberine and alkaloids research
- Keywords
- bile acids, bile acid signaling, metabolic disorders, obesity, type 2 diabetes, hypertriglyceridemia, atherosclerosis, nonalcoholic steatohepatitis, therapeutic target, drug development
- MeSH terms
- Animals, Bile Acids and Salts, Humans, Metabolic Diseases, Signal Transduction, Drug Delivery Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.